TAVR or Surgery for Intermediate-Risk Patients? (GARY Registry)

New findings from the GARY (German Aortic Valve Registry) registry show that intermediate-risk patients with severe aortic stenosis presented significantly higher mortality at 1 year when treated with transcatheter aortic valve replacement (TAVR) rather than with conventional surgery.

 

Results reflect everyday realities, which might include various bias tipping the scales towards one strategy or the other, and which could have contributed to the results.

 

The survival difference favoring surgery shown in the registry persisted even after propensity-score matching, but that does not rule out the presence of many other unadjusted confounding variables.

 

Almost 50,000 patients were enrolled in the GARY registry between January 2011 and December 2013, of whom 22.7% presented intermediate surgical risk (logistic EuroSCORE 10-20%).

 

Overall, 5997 patients who underwent TAVR or isolated valve surgery were included in the analysis.

 

Baseline differences between groups were striking, since patients who underwent TAVR showed higher surgical risk, presented greater age, worse heart failure, more prior myocardial infarction, more atrial fibrillation The most frequent reasons underlying the choice of TAVR over surgery were patient age and frailty.

 

Many of these factors might have affected the rate of all-cause mortality at a year: 8.9% for surgery vs. 16.6% for TAVR (p < 0.001).

 

The decision to choose one strategy over the other was made by a heart team in over 90% of patients, and it is clearly impossible to adjust for medical opinion.

 

Original title: Patients at Intermediate Surgical Risk Undergoing Isolated Interventional or Surgical Aortic Valve Replacement for Severe Symptomatic Aortic Valve Stenosis.

Presenter: Werner N.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...

J-Valve for Chronic AR: 30-Day Outcomes of Transfemoral Valve J-Valve in Chronic Aortic Regurgitation

Chronic aortic regurgitation (AR) poses a significant challenge as far as transcatheter alternatives go due to the absence of calcification and a suitable anchoring...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...